Deleted Journal, Journal Year: 2024, Volume and Issue: 1(2), P. 134 - 149
Published: Dec. 1, 2024
Niclosamide, an FDA-approved anti-parasitic drug, has demonstrated significant potential as a repurposed anti-cancer agent due to its ability interfere with multiple oncogenic pathways. However, clinical application been hindered by poor solubility and bioavailability. Lipid-based nanocarrier systems such liposomes, solid lipid nanoparticles (SLNs), nanostructured carriers (NLCs), nanoemulsions (LNE), along prodrugs, have successfully employed researchers overcome these limitations improve niclosamide’s pharmacokinetic profile. Lipids are the core organic compounds which serve foundation of advanced drug delivery methods in turn play critical role enhancing therapeutic efficacy through improving encapsulate niclosamide, protect it from degradation, facilitate release, may targeted future. While niclosamide holds anticancer multi-pathway inhibitory effects, challenges associated bioavailability rapid clearance underscore need for innovative chemical modifications unlock full potential. This review aims present latest instances lipid-based compile successful strategies be when aiming develop effective therapies.
Language: Английский